GSK Expands Eastern Partnerships with $30M Option on DualityBio’s Preclinical ADC

GSK's New Partnership:
GlaxoSmithKline (GSK) has secured an option to license DualityBio's preclinical antibody-drug conjugate (ADC) for $30 million145.

Geographical Scope:
The licensing agreement covers territories outside of mainland China, Hong Kong, and Macau45.

Financial Terms:
The deal includes $30 million in upfront and preclinical milestone payments45.

Strategic Expansion:
This move marks another instance of GSK expanding its partnerships in the East, specifically with Chinese biotech companies145.

DualityBio's Role:
DualityBio, a Chinese biotech firm, has granted GSK the option to license its ADC, indicating a strategic collaboration between the two companies45.

Sources:

1. https://www.fiercebiotech.com

4. https://www.fiercebiotech.com/biotech/gsk-goes-east-again-snagging-option-preclinical-dualitybio-adc-30m

5. https://sfbn.org/san-francisco-biotech-news/2024/12/04/gsk-goes-east-again-snagging-option-on-preclinical-dualitybio-adc-for-30m/